Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

sion (abstract #3594) during the American Association for Cancer Research's 100th Annual Meeting 2009 at the Colorado Convention Center in Denver.

Phase 1 Study Design and Results

Poniard's randomized, open-label, dose-ranging Phase 1 study was conducted at clinical sites in the United States. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously to patients with advanced solid tumor malignancies. Bioavailability refers to the fraction of an administered dose of an unchanged drug that reaches systemic circulation. In the first part of this two-part trial, patients with advanced solid tumor malignancies were randomized to a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200 mg, 300 mg or 400 mg). Four weeks later, they received a second single picoplatin dose administered via the other route. In the second part of the trial, patients received only a single oral dose of picoplatin (including doses of 50 mg and 100 mg).

Final results showed that oral picoplatin achieved oral bioavailability of nearly 100 percent at doses of 50 mg and 100 mg. No meaningful differences in pharmacokinetics were observed between the two formulations. All doses of the oral dose were well tolerated. No serious adverse events related to treatment were noted following administration of the oral dose.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other pl
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... Dress company LunaDress has recently announced its 2015 ... offering big discounts on all of its special occasion dresses ... own a perfect wedding gown. If you have no idea ... to LunaDress. Many different wedding dress styles and our dress ... and enjoy the current special offer, up to 80% off," ...
(Date:12/20/2014)... December 20, 2014 Recently, VogueQueen.com, a ... VogueQueen Big Sale Online for 2015. Great ... All new and old consumers can get a discount, ... at the company’s website before January 30, 2015. , ... dresses and launched a prom dress promotion. Many customers ...
(Date:12/20/2014)... 20, 2014 Atore, Inc, (San Francisco, ... launched first birthday focused portal on December 17th, 2014. ... launched in both US and Japan. , MERRY BIRTHDAY ... http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE is part ... the world. , Features, Choose from thousands of stock ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
(Date:12/19/2014)... Today, Balfleet.com , a leading dress ... formal dress promotion. All the old and new customers ... , Balfleet.com is well-known for its high quality trendy ... cocktail dresses and more. Its formal dresses are quality ... they can create an elegant look when paired with ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2
... The Speaker of Lok Sabha, Shri Somnath Chatterji has said ... priority in policy making and implementation of programmes. // ... the country and the children at Vaatsalaya Mela here today, ... that still women and children went struggling for their rightful ...
... certain inhaled asthma medications and similar chemicals produced in ... worsen conditions like lupus, heart failures, asthma and other ... led by Raymond Penn, Ph.D., and Matthew Loza, Ph.D, ... out the research, found that beta-agonists, such as those ...
... engaging people cured of leprosy to fight the stigma of the ... of leprosy in the state has fallen to 1.56 percent in ... 'Lok Doots' (Messenger of People), as the cured are called, have ... ,For instance, the prevalence rate in Ranchi has gone up ...
... cardiac arrest is a common and deadly event. Twenty percent of ... a sudden cardiac arrest; //barely 5% of people who have one ... comes out of the blue, but a new study suggests that ... 2006 issue of the Harvard Heart Letter. ,Studying cardiac arrest ...
... The Massachusetts Biologic Laboratories (MBL) of the University of ... India today announce //the formation of an historic collaboration ... approach for preventing rabies in people. ,The institutions ... antibody (MAB) created by scientists at the MBL, in ...
... often multi-tasking and walking the tightrope to make a success ... they can chew! Though, such qualities //are the epitome of ... a pat on the back for such back-breaking endeavors. ... ill-health due to the build up of stress and over ...
Cached Medicine News:Health News:Women and Children Issues Should Get Priority in India 2Health News:The Immune System May Be Altered By Certain Chemicals 2Health News:International Collaboration Takes Aim at Rabies 2Health News:International Collaboration Takes Aim at Rabies 3
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
(Date:12/17/2014)... NEW YORK , Dec. 17, 2014 /PRNewswire-USNewswire/ ... resonance imaging (MRI), the MRI market is seeing ... cardiovascular and breast MRI scans account for the ... providing a higher resolution of images, which are creating ... resonance imaging (MRI) market is growing at a ...
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. (NYSE ... closing of its offering of $125 million aggregate principal ... "Notes").  The Notes were offered and sold only to ... Securities Act of 1933, as amended (the "Securities Act"). ... rate of 3.75% per year, payable semiannually in arrears ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... both ethical and practical grounds, direct programming is ... pluripotent stem,cells.", WASHINGTON, Nov. 20 Two ... Cell unveil a proven way to,generate patient-matched human ... use of human embryos or human or animal ...
... of circulating cancer cells in 40,billion blood cells, ... WARREN, N.J., Nov. 20 Veridex, LLC ... (FDA) has granted an,expanded clearance for the CellSearch(TM) ... monitoring of metastatic colorectal cancer. CellSearch is currently,approved ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 2FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 3FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 4
... Heartlab delivers the performance and ... information management systems. As the ... services set the benchmark. When ... high-speed performance and technological longevity, ...
The only catheter designed specially for visualization of peripheral vessels: carotids, renals, and illiacs...
... technology constructs images using second harmonic ... and noise than fundamental-frequency components., Pure ... transmit distortion-free, fundamental-frequency ultrasound beams. And ... a pure sinusoidal wave, both the ...
AngioSpeed V series, it is an Angiography system designed for vascular treatment in various radiological regions, cardiology, and neurology. SHIMADZU brings you a single system with all units fused t...
Medicine Products: